Pharsight

Drugs that contain Degarelix Acetate

1. Firmagon patents expiration

FIRMAGON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5925730 FERRING GnRH antagonists
May, 2021

(2 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10973870 FERRING Methods of treating prostate cancer with GnRH antagonist
Feb, 2029

(4 years from now)

US9579359 FERRING Method of treating prostate cancer with GnRH antagonist
Feb, 2029

(4 years from now)

US10729739 FERRING Methods of treating prostate cancer with GnRH antagonist
Feb, 2029

(4 years from now)

US11766468 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(8 years from now)

US9415085 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(8 years from now)

US11826397 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(8 years from now)

US10695398 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 24, 2013

NCE-1 date: 24 December, 2012

Market Authorisation Date: 24 December, 2008

Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect; Method of treating prostate cancer; Gnrh antagonist indicated for trea...

Dosage: POWDER;SUBCUTANEOUS

How can I launch a generic of FIRMAGON before it's drug patent expiration?
More Information on Dosage

FIRMAGON family patents

Family Patents